文献速递肝病

脂肪性肝病患者使用他汀的长期肝脏相关结局与肝硬度进展

Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease.
PubMed 文献 · Gut · 2024-10-07

这项多中心队列研究纳入7988例至少接受两次振动控制瞬时弹性成像的代谢相关脂肪性肝病患者,中位随访4.6年。基线40.5%使用他汀,17%存在代偿期进展性慢性肝病。他汀使用与较低的全因死亡、肝脏相关临床事件及肝硬度进展风险相关,但与肝硬度逆转无关。

要点

  • 他汀使用与全因死亡风险降低相关(校正HR=0.233;95%CI 0.127至0.426)。
  • 他汀使用与肝脏相关临床事件风险降低相关(校正HR=0.380;95%CI 0.268至0.539)。
  • 他汀使用与代偿期进展性慢性肝病和非代偿期进展性慢性肝病的肝硬度进展率降低相关,但与肝硬度逆转无关。

核心结论

  • 在代谢相关脂肪性肝病患者中,他汀使用与相对较低的长期全因死亡、肝脏相关临床事件和肝硬度进展风险相关。

研究设计与样本

  • 这项队列研究在16家三级转诊中心收集至少接受两次振动控制瞬时弹性成像检查的代谢相关脂肪性肝病患者数据。
  • 共随访7988例患者,基线肝硬度测量值为5.9 kPa(IQR 4.6-8.2),中位随访4.6年。
  • 采用Cox回归分析他汀使用与全因死亡和肝脏相关临床事件的关联,并按代偿期进展性慢性肝病(基线肝硬度测量值≥10 kPa)分层。

主要发现

  • 基线时40.5%的患者使用他汀,17%存在代偿期进展性慢性肝病。
  • 他汀使用与较低的全因死亡风险显著相关(校正HR=0.233;95%CI 0.127至0.426)。
  • 他汀使用与较低的肝脏相关临床事件风险显著相关(校正HR=0.380;95%CI 0.268至0.539)。
  • 他汀使用与代偿期进展性慢性肝病较低的肝硬度进展率相关(HR=0.542;95%CI 0.389至0.755)。
  • 他汀使用与非代偿期进展性慢性肝病较低的肝硬度进展率相关(校正HR=0.450;95%CI 0.342至0.592),但与肝硬度逆转无关(校正HR=0.914;95%CI 0.778至1.074)。

关键数值与推荐

  • 代偿期进展性慢性肝病定义为基线肝硬度测量值≥10 kPa。
  • 代偿期进展性慢性肝病的肝硬度进展定义为肝硬度测量值增加≥20%。
  • 非代偿期进展性慢性肝病的肝硬度进展定义为肝硬度测量值从<10 kPa升至≥10 kPa或肝硬度测量值增加。
  • 肝硬度逆转定义为肝硬度测量值从≥10 kPa降至<10 kPa或代偿期进展性慢性肝病的肝硬度测量值降低≥20%。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Statins have multiple benefits in patients with metabolic-associated steatotic liver disease (MASLD). AIM: To explore the effects of statins on the long-term risk of all-cause mortality, liver-related clinical events (LREs) and liver stiffness progression in patients with MASLD. METHODS: This cohort study collected data on patients with MASLD undergoing at least two vibration-controlled transient elastography examinations at 16 tertiary referral centres. Cox regression analysis was performed to examine the association between statin usage and long-term risk of all-cause mortality and LREs stratified by compensated advanced chronic liver disease (cACLD): baseline liver stiffness measurement (LSM) of ≥10 kPa. Liver stiffness progression was defined as an LSM increase of ≥20% for cACLD and from <10 kPa to ≥10 or LSM for non-cACLD. Liver stiffness regression was defined as LSM reduction from ≥10 kPa to <10 or LSM decrease of ≥20% for cACLD. RESULTS: We followed up 7988 patients with baseline LSM 5.9 kPa (IQR 4.6-8.2) for a median of 4.6 years. At baseline, 40.5% of patients used statins, and cACLD was present in 17%. Statin usage was significantly associated with a lower risk of all-cause mortality (adjusted HR=0.233; 95% CI 0.127 to 0.426) and LREs (adjusted HR=0.380; 95% CI 0.268 to 0.539). Statin usage was also associated with lower liver stiffness progression rates in cACLD (HR=0.542; 95% CI 0.389 to 0.755) and non-cACLD (adjusted HR=0.450; 95% CI 0.342 to 0.592), but not with liver stiffness regression (adjusted HR=0.914; 95% CI 0.778 to 1.074). CONCLUSIONS: Statin usage was associated with a relatively lower long-term risk of all-cause mortality, LREs and liver stiffness progression in patients with MASLD.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Zhou XD, Kim SU, Yip TC, et al. Long-term liver-related outcomes and liver stiffness progression of statin usage in steatotic liver disease. Gut. 2024. PMID: 39089860. doi:10.1136/gutjnl-2024-333074

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。